{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:25:10Z","timestamp":1790443510749,"version":"4.1.0"},"publisher-location":"Cham","reference-count":44,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319524429","type":"print"},{"value":"9783319524443","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/7854_2016_34","type":"book-chapter","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T13:54:05Z","timestamp":1472478845000},"page":"1-18","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The Growing Problem of New Psychoactive Substances (NPS)"],"prefix":"10.1007","author":[{"given":"Bertha K.","family":"Madras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,30]]},"reference":[{"key":"34_CR1","doi-asserted-by":"crossref","unstructured":"Nichols DE, Fantegrossi WE (2013) Emerging designer drugs. In: Madras B, Kuhar M (eds) The effects of drug abuse on the human nervous system. Academic Press, Cambridge, MA, pp 575\u2013596","DOI":"10.1016\/B978-0-12-418679-8.00019-8"},{"key":"34_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/YCO.0000000000000071","volume":"27","author":"E Papaseit","year":"2014","unstructured":"Papaseit E, Farr\u00e9 M, Schifano F, Torrens M (2014) Emerging drugs in Europe. Curr Opin Psychiatry 27:243\u2013250","journal-title":"Curr Opin Psychiatry"},{"key":"34_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2012.07.011","volume":"39","author":"P Deluca","year":"2012","unstructured":"Deluca P, Davey Z, Corazza O et al (2012) Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry 39:221\u2013226","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"34_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/dta.1686","volume":"6","author":"SD Brandt","year":"2014","unstructured":"Brandt SD, King LA, Evans-Brown M (2014) The new drug phenomenon. Drug Test Anal 6:587\u2013597","journal-title":"Drug Test Anal"},{"key":"34_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.drugalcdep.2014.07.009","volume":"143","author":"EE Bonar","year":"2014","unstructured":"Bonar EE, Ashrafioun L, Ilgen MA (2014) Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates. Drug Alcohol Depend 143:268\u2013271","journal-title":"Drug Alcohol Depend"},{"key":"34_CR6","unstructured":"WHO (2014) http:\/\/www.who.int\/medicines\/areas\/quality_safety\/36thecddmeet\/en\/"},{"key":"34_CR7","unstructured":"WHO (2015) http:\/\/www.who.int\/medicines\/access\/controlled-substances\/ecdd\/en\/"},{"key":"34_CR8","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1124\/jpet.106.105312","volume":"319","author":"BK Madras","year":"2006","unstructured":"Madras BK, Fahey MA, Goulet M et al (2006) Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. J Pharmacol Exp Ther 319:570\u2013585","journal-title":"J Pharmacol Exp Ther"},{"key":"34_CR9","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1021\/jm050797a","volume":"49","author":"PC Meltzer","year":"2006","unstructured":"Meltzer PC, Butler D, Deschamps JR, Madras BK (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49:1420\u20131432","journal-title":"J Med Chem"},{"key":"34_CR10","unstructured":"WHO 5.3 (2015) http:\/\/www.who.int\/medicines\/access\/controlled-substances\/5.3_Alpha-PVP_CRev.pdf?ua=1"},{"key":"34_CR11","unstructured":"DEA (2014) Special report: synthetic cannabinoids and cathinones reported in NFLIS, 2010\u20132013. http:\/\/www.deadiversion.usdoj.gov\/nflis\/spec_rpt_CathCan_2013.pdf"},{"key":"34_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/emermed-2011-200747","volume":"30","author":"DM Wood","year":"2013","unstructured":"Wood DM, Greene SL, Dargan PI (2013) Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: mephedrone (4-methylmethcathinone) control appears to be effective using this model. Emerg Med J 30:70\u201371","journal-title":"Emerg Med J"},{"key":"34_CR13","unstructured":"EMCDDA (2015) New psychoactive substances in Europe: an update from the EU Early Warning System March 2015. http:\/\/www.emcdda.europa.eu\/html.cfm\/index44847EN.html"},{"key":"34_CR14","unstructured":"EMCDDA (2015) European Drug Report 2015: trends and developments. http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_239505_EN_TDAT15001ENN.pdf"},{"key":"34_CR15","unstructured":"EMCDDA (2015b) Internet and Drug Markets http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/2155\/TDXD16001ENN_FINAL.pdf"},{"key":"34_CR16","unstructured":"EMCDDA EU Early Warning System (2015) New psychoactive substances in Europe: an update from the EU early warning system March 2015. http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_235958_EN_TD0415135ENN.pdf"},{"key":"34_CR17","unstructured":"UNODC: United Nations Office of Drugs and Crime (2015) World Drug Report 2015. http:\/\/www.unodc.org\/documents\/wdr2015\/World_Drug_Report_2015.pdf"},{"key":"34_CR18","unstructured":"DEA (2015) http:\/\/www.dea.gov\/docs\/2015%20NDTA%20Report.pdf"},{"key":"34_CR19","volume-title":"Monitoring the future national results on adolescent drug use: overview of key findings, 2015","author":"LD Johnston","year":"2016","unstructured":"Johnston LD, O\u2019Malley PM, Miech RA et al (2016) Monitoring the future national results on adolescent drug use: overview of key findings, 2015. Institute for Social Research, the University of Michigan, Ann Arbor, MI"},{"key":"34_CR20","doi-asserted-by":"crossref","unstructured":"Trecki J, Gerona RR, Schwartz MD (2015) Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373:103\u2013107","DOI":"10.1056\/NEJMp1505328"},{"key":"34_CR21","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979\u2013980","journal-title":"Science"},{"key":"34_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104784","volume":"9","author":"C Bonnet","year":"2014","unstructured":"Bonnet C, Rusz J, Megrelishvili M et al (2014) Eye movements in ephedrone-induced parkinsonism. PLoS One 9, e104784","journal-title":"PLoS One"},{"key":"34_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3109\/15563650.2014.933231","volume":"52","author":"A Schneir","year":"2014","unstructured":"Schneir A, Ly BT, Casagrande K et al (2014) Comprehensive analysis of \u201cbath salts\u201d purchased from California stores and the internet. Clin Toxicol (Phila) 52:651\u2013658","journal-title":"Clin Toxicol (Phila)"},{"key":"34_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.forsciint.2013.10.002","volume":"233","author":"KA Seely","year":"2013","unstructured":"Seely KA, Patton AL, Moran CL et al (2013) Forensic investigation of K2, Spice, and \u201cbath salt\u201d commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int 233:416\u2013422","journal-title":"Forensic Sci Int"},{"key":"34_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.drugalcdep.2011.02.011","volume":"118","author":"RL Carhart-Harris","year":"2011","unstructured":"Carhart-Harris RL, King LA, Nutt DJ (2011) A web-based survey on mephedrone. Drug Alcohol Depend 118:19\u201322","journal-title":"Drug Alcohol Depend"},{"key":"34_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/hup.2299","volume":"28","author":"O Corazza","year":"2013","unstructured":"Corazza O, Assi S, Simonato P et al (2013) Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project. Hum Psychopharmacol 28:317\u2013323","journal-title":"Hum Psychopharmacol"},{"key":"34_CR27","doi-asserted-by":"publisher","first-page":"15150","DOI":"10.1523\/JNEUROSCI.3223-14.2014","volume":"34","author":"MH Baumann","year":"2014","unstructured":"Baumann MH, Solis E Jr, Watterson LR et al (2014) Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci 34:15150\u201315158","journal-title":"J Neurosci"},{"key":"34_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1345\/aph.1Q628","volume":"46","author":"JA Fass","year":"2012","unstructured":"Fass JA, Fass AD, Garcia AS (2012) Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann Pharmacother 46:436\u2013441","journal-title":"Ann Pharmacother"},{"key":"34_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13181-011-0193-z","volume":"8","author":"JM Prosser","year":"2012","unstructured":"Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33\u201342","journal-title":"J Med Toxicol"},{"key":"34_CR30","unstructured":"NFLIS-DEA (2014) https:\/\/www.nflis.deadiversion.usdoj.gov\/DesktopModules\/ReportDownloads\/Reports\/NFLIS2014AR.pdf"},{"key":"34_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","volume":"144","author":"MS Castaneto","year":"2014","unstructured":"Castaneto MS, Gorelick DA, Desrosiers NA et al (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12\u201341","journal-title":"Drug Alcohol Depend"},{"key":"34_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1521-0391.2012.00240.x","volume":"21","author":"EW Gunderson","year":"2012","unstructured":"Gunderson EW, Haughey HM, Ait-Daoud N et al (2012) \u201cSpice\u201d and \u201cK2\u201d herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 21:320\u2013326","journal-title":"Am J Addict"},{"key":"34_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.pnpbp.2012.04.017","volume":"39","author":"KA Seely","year":"2012","unstructured":"Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39:234\u2013243","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"34_CR34","doi-asserted-by":"crossref","unstructured":"Hermanns-Clausen M, Kithinji J, Spehl M et al (2016) Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project. Drug Test Anal 2016 [Epub ahead of print]","DOI":"10.1002\/dta.1936"},{"key":"34_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","volume":"54","author":"RJ Tait","year":"2016","unstructured":"Tait RJ, Caldicott D, Mountain D et al (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 54:1\u201313","journal-title":"Clin Toxicol (Phila)"},{"key":"34_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.09.030","volume":"157","author":"JB Zawilska","year":"2015","unstructured":"Zawilska JB, Andrzejczak D (2015) Next generation of novel psychoactive substances on the horizon - A complex problem to face. Drug Alcohol Depend 157:1\u201317","journal-title":"Drug Alcohol Depend"},{"key":"34_CR37","doi-asserted-by":"crossref","unstructured":"Coviello L, Sohn Y, Kramer AD et al (2014) Detecting emotional contagion in massive social networks. PLoS One 12;9(3):e90315","DOI":"10.1371\/journal.pone.0090315"},{"key":"34_CR38","doi-asserted-by":"crossref","unstructured":"Kim DA, Hwong AR, Stafford D, Hughes et al (2015) Social network targeting to maximise population behaviour change: a cluster randomised controlled trial. Lancet 386:145\u2013153","DOI":"10.1016\/S0140-6736(15)60095-2"},{"key":"34_CR39","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/archpediatrics.2012.1372","volume":"166","author":"HB Shakya","year":"2012","unstructured":"Shakya HB, Christakis NA, Fowler JH (2012) Parental influence on substance use in adolescent social networks. Arch Pediatr Adolesc Med 166:1132\u20131139","journal-title":"Arch Pediatr Adolesc Med"},{"key":"34_CR40","unstructured":"YouTube https:\/\/www.youtube.com\/watch?v\u2009=\u2009-WWNwW0aDh4"},{"key":"34_CR41","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/dta.1523","volume":"7\u20138","author":"LA King","year":"2014","unstructured":"King LA, Ujv\u00e1ry I, Brandt SD (2014) Drug laws and the \u2018derivative\u2019 problem. Drug Test Anal 7\u20138:879\u2013883","journal-title":"Drug Test Anal"},{"key":"34_CR42","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2174\/138620708784911483","volume":"11","author":"NH Jensen","year":"2008","unstructured":"Jensen NH, Roth BL (2008) Massively parallel screening of the receptorome. Comb Chem High Throughput Screen 11:420\u2013426","journal-title":"Comb Chem High Throughput Screen"},{"key":"34_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0165-6147(03)00027-0","volume":"24","author":"DJ Sheffler","year":"2003","unstructured":"Sheffler DJ, Roth BL (2003) Salvinorin A: the \u201cmagic mint\u201d hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24:107\u2013109","journal-title":"Trends Pharmacol Sci"},{"key":"34_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1517\/17425255.1.3.377","volume":"1","author":"V Setola","year":"2005","unstructured":"Setola V, Roth BL (2005) Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on \u2018fen-phen\u2019. Expert Opin Drug Metab Toxicol 1:377\u2013387","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Current Topics in Behavioral Neurosciences","Neuropharmacology of New Psychoactive Substances (NPS)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2016_34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T06:16:59Z","timestamp":1700201819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2016_34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319524429","9783319524443"],"references-count":44,"URL":"https:\/\/doi.org\/10.1007\/7854_2016_34","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"30 August 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}